Why the study?
Does perfusion using melphalan and dactinomycin improve survival in patients with sarcomas of the limbs?
Population
87 patients (79 with soft-tissue sarcomas and 8 with sarcomas of bone and cartilage)
Design
Case_series
Follow-up
Up to 10 years
Authors
Loading...
Case series survival rates may support evaluation in soft-tissue sarcomas; leaves open efficacy versus standard care in controlled trials.
Does perfusion using melphalan and dactinomycin improve survival in patients with sarcomas of the limbs?
Perfusion with melphalan and dactinomycin provides disease control and reduces necessary surgical resection for soft-tissue sarcomas of the limbs, but is not recommended for bone or cartilage sarcomas.
Charles M. McBride (1974) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: